Sep 22, 2017 10:00am EDT James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Aug 30, 2017 8:00am EDT Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
Jul 31, 2017 4:00pm EDT Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
Jun 05, 2017 9:50am EDT Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2017 8:00am EDT Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2017 8:00am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
May 16, 2017 7:59am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
May 10, 2017 7:30am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
